Translational Cancer Research

期刊简介：Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.

【译文】转化癌症研究（转化癌症研究 TCR；印刷版 ISSN：2218-676X；在线 ISSN 2219-6803；http://tcr.amegroups.com/）是一本开放获取、同行评审的期刊，被科学引文索引扩展（SCIE）收录。TCR发表关于新型治疗干预措施的研究实验室研究以及评估癌症新治疗模式的临床试验；包括风险评估、细胞和分子特征、预防、检测、诊断和治疗人类癌症的新研究调查结果，总体目标是提高癌症患者的临床护理。TCR的关注点是原创、同行评审、基于科学的研发，成功推动临床医学向改善患者生活质量的总体目标迈进。编辑和由科学家、临床科学家以及其他专家组成的国际顾问小组将TCR文章的质量标准定得很高。我们接受原创文章、综述文章、社论和简报。